Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease affecting motor neurons of the brain, brainstem and spinal cord. To date, mutations in more than 30 genes have been linked to the pathogenesis of ALS. Among them, SOD1, FUS and TARDBP are ranked as the three most common genes associated with ALS. However, no mutation analysis has been reported in central-southern China. In this study, we sequenced SOD1, FUS and TARDBP in a central-southern Chinese cohort of 173 patients with ALS (15 familial ALS and 158 sporadic ALS) to detect mutations. As a result, five missense mutations in SOD1, namely, p.D101N, p.D101G, p.C111Y, p.N86S and p.V87A, were identified in three unrelated familial probands and three sporadic cases; two mutations in FUS were found in two unrelated familial probands, including an insertion mutation (p.P525_Y526insY) and a missense mutation (p.R521H); no variants of TARDBP were observed in patients. Therefore, SOD1 mutations were present in 20.0% of familial ALS patients and 1.9% of sporadic ALS patients, while FUS mutations were responsible for 13.3% of familial ALS cases, and TARDBP mutations were rare in either familial or sporadic ALS cases. This study broadens the known mutational spectrum in patients with ALS and further demonstrates the necessity for genetic screening in ALS patients from central-southern China.
. The pathogenesis of ALS is complicated, and genetic factors play a relatively important role in patients with ALS. The pattern of inheritance can be autosomal dominant, autosomal recessive, or X-linked 5 . Approximately 5-10% of patients with ALS have a positive family history of the disease.
To date, mutations in more than 30 genes have been linked to the pathogenesis of ALS, but mutations in only a few of them, including SOD1, FUS, TARDBP and C9orf72, are present in a significant number of ALS cases 6, 7 . SOD1 was the first gene associated with ALS to be identified, and more than 166 mutations have been successively reported 2 , which could account for the occurrence of 20% of familial ALS (fALS) cases and 1-4% of sporadic ALS (sALS) cases 8 . FUS mutations have been detected in 4-6% of fALS cases and 0.7-1.8% of sALS cases 9 . Most of these mutations are located in exons 5-6 and exons 14-15 of FUS 10 . With regards to TARDBP, more than 42 mutations have been found in 5% of fALS cases and 2% of sALS cases 5 . However, there are still no reports of these mutations in central-southern China. Therefore, we performed a comprehensive and systematic screening of SOD1, FUS and TARDBP genes to further analyze the types of mutations and their frequency in patients with ALS from central-southern China. In addition, we further analyzed the clinical characteristics of ALS patients carrying genetic mutations.
Results
Genetic Results. Three reported mutations of SOD1 (p.D101N, p.D101G and p.C111Y) were identified in three unrelated fALS patients, and three reported mutations of SOD1 (p.N86S, p.V87A and p.C111Y) were identified in three unrelated sALS patients. With regards to FUS, one novel mutation (p.P525_Y526insY) and one previously reported mutation (p.R521H) were detected in two unrelated fALS probands. However, no mutations in TARDBP were identified. None of these mutations were found in the 500 healthy individuals testd. Genetic results and pathogenic predictions are presented in Table 1 . In addition, the mean age of onset for mutation carriers and non-carriers was 44.0 ± 15.2 and 49.0 ± 12.2 years, respectively. The Mann-Whitney U test revealed that there was no significant difference between the groups (p = 0.31). No significant differences was found between groups when comparing in male to female ratio (p = 0.44).
SOD1 mutation in fALS. The c.335G> A, p.C111Y mutation was identified in a fALS proband ( Fig. 1 M23969: I2). At age 68, she developed a slowly progressive distal weakness in her upper left limb, and one month later, the weakness spread to the lower left limb, while fasciculation and atrophy in the upper left limb were observed. A neurological examination revealed signs of upper motor neuron (UMN) damage, and an electromyogram indicated the presence of generalized chronic progressive neurogenic damage. Her daughter ( Fig. 1 M23969: II4) developed progressive weakness in her lower left limb at age 46 and quickly developed weakness, dysarthria and dysphagia in all four extremities within one year. She then died of respiratory failure after 18 months. Although her daughter carried the same mutation, she had an earlier age of onset and a seemingly worse clinical phenotype than her mother. Her sons did not carry this mutation or share this clinical phenotype.
The c.304G> A, p.D101N mutation was detected in another fALS patient ( Fig. 1 M13948: III2 ). He began undergoing gradually progressive weakness in his upper right limb at age 26. The distal weakness was predominant, preventing him from performing daily work. One year later, the weakness gradually spread to the lower limbs and upper left limb. Fasciculation and muscle atrophy was observed in all extremities. The tendon reflex was active, the Babinski reflex was detected, and the electromyogram demonstrated chronic reinnervation in all extremities. Two years later, he experienced worsening limb weakness and the development of dysarthria and dysphagia. The patient died of respiratory failure three years after the onset of symptoms. His father ( Fig. 1 M13948: II2) began suffering from weakness of the upper limbs at the age of 38. Two years later, his remaining limbs and bulbar muscles were also weakened. Finally, he died of respiratory failure at age 41.
The third SOD1 mutation c.305A> G, p.D101G was identified in a 47-year-old female who first presented with progressive weakness and systemic fasciculations in her upper left limb ( Fig. 1 M31584: IV6) . Four months later, she experienced worsening weakness in her upper left limb, and she felt weak in her other limbs. Six months later, dysphagia and dysarthria occurred. Upon admission, a neurologic examination revealed the presence of atrophy, reduced muscle strength, areflexia, and the absence of bilateral Babinski and Hoffman signs in her left hand. The electromyogram revealed extensive chronic neurological changes. Her son was verified as a carrier of the c.305A> G mutation, but he did not present with clinically relevant ALS symptoms ( Fig. 1 M31584: V4 ). Other members of the family experienced a similar, approximately two-year disease course and finally died of respiratory failure in a comparable manner to the proband. Unfortunately, the DNA samples of these family members were unavailable for genetic analysis. Moreover, IV1, IV4 and IV9 did not share this mutation.
SOD1 mutations in sALS. Three mutations (p.N86S, p.V87A and p.C111Y) were observed in three unrelated sALS patients. A 58-year-old female patient with the c.260A> G, p.N86S mutation (Fig. 1 M23225) was primarily characterized by progressive weakness and muscle atrophy in her lower limbs beginning at the age of 55. Her tendon reflex was normal and the Babinski reflex was absent. The electromyogram revealed chronic reinnervation in her lower limbs, distal left limb, and paravertebral muscles. The c.335G> A, p.C111Y mutation ( Fig. 1 M18301) was identified in a juvenile-onset sALS patient suffering from an aggressive disease progression with muscle atrophy, worsening fasciculation and weakness in all limbs. His deep tendon reflexes were active in all limbs, and the Babinski reflex was present. One year later, he started suffering from occasional choking while drinking and mild dysarthria. The c.263T> C, p.V87A mutation (Fig. 1 M23362) was identified in a sALS patient who developed weakness and muscle atrophy in the upper left limb at 51 years of age. For 24 months, the muscle weakness gradually progressed to the upper right limb and the lower extremities. Physical examinations showed that the deep tendon reflexes of all limbs were brisk and the Hoffman sign was present. Electromyography revealed extensive chronic progressive neurological damage in all four extremities. and disease duration. III:3 and III:4 did not share this mutation. Therefore, the c.1562G> A, p.R521H mutation completely co-segregated with the disease phenotype within this family. The novel mutation c.1575_1576insTAT, p.P525_Y526insY was identified in a female proband ( Fig. 2 M17299:  III2) . Her initial symptoms, beginning at age 43, were progressive weakness of the upper left limb and slow progression of weakness into the upper right limb and lower limbs. Meanwhile, muscle atrophy of the upper left limb occurred. Due to the proximal weakness, she could not lift her arms or go down stairs. A neurological examination showed that the tendon reflexes in her upper limbs were disappearing, while the tendon reflexes in her lower limbs were pathologically brisk. The electromyogram showed general spontaneous denervation activity and a loss of motor units in the tibialis anterior. Approximately 28 months later, the weakness in her limbs, mild dysarthria and dysphagia worsened, and she finally died of respiratory failure. Her father presented with a similar clinical phenotype and disease duration. Unluckily, his DNA sample was not obtained. III:1, III:3, and III:4 did not carry this mutation and share this clinical phenotype.
Discussion
In this study, we systematically described the frequencies of SOD1, FUS and TARDBP mutations in patients with ALS from central southern China. Mutations in SOD1 were present in 20.0% of fALS patients and 1.9% of sALS patients, which is consistent with previous studies in western populations 8 , and indicates that SOD1 mutations play a key role in the pathology of ALS patients from different ethnicities. In addition, the frequency of FUS mutation was approximately 13.3% in fALS patients, which is consistent with reports from several other populations [11] [12] [13] [14] , but is higher than the frequencies found in Catalan (8%) 15 , German (2.4-6.9%) 16, 17 , Italian (4.4%) 12 , and Belgian (2.9%) 18 populations. This difference may be due to small sample sizes and the differing ethnicities of fALS patients. Although FUS mutations were not found in sALS patients, this is probably due to both the selective detection of exons in mutational hotspot regions and the use of small sample sizes. Zou ZY reported that FUS mutations could be present in approximately 1.0% of northern Chinese sALS patients, which is similar to the 1.6% mutation frequency found in Korean patients and the 1.25% mutation frequency found Italian patients 12, 14, 19, 20 . With regards to the frequency of TARDBP mutation, it appears that the frequency of TARDBP mutations in Caucasian populations (Italy: 2.7%; France and Quebec: 4.5%) was higher than that in Asian populations [21] [22] [23] [24] . The prevalence was different, even within the same population. Zou ZY reported that TARDBP mutations were only present in 0.73% of northern Chinese sALS patients 25 , but Soong's research showed that TARDBP mutations have a higher frequency (4.3%), second only to SOD1 mutations (7.5%), in Taiwanese ALS patients, especially fALS patients 26 . Undeniably, our study did not identify TARDBP mutations, which is probably due to our small sample sizes and the ethnic differences of our study population. In addition, we previously reported that C9orf72 expansion was present in approximately 8.33% of fALS patients, which was lower than the frequency of FUS and SOD1 mutation 27 . This study indicates that in Chinese ALS patients, we should screen SOD1 mutations first, then FUS mutations, and then C9orf72 and TARDBP mutations.
In current study, four mutations of SOD1 (p.N86S, p.V87A, p.D101N, p.D101G) were identified firstly in Chinese ALS patients. p.N86S mutation was previously first identified in a juvenile onset case of fALS, all reported affected family members present worse phenotype and ephemeral duration 28 , while in our study, the sALS patients with this same mutation showed only mild clinical phenotypes. Although Andersen had previously reported the p.V87A mutation, the clinical features of the patients were not detailed 29 . It was noted that the patients with the p.V87A mutation were prone to experience relatively typical ALS-related clinical symptoms. The third mutation we identified, p.D101N, has been associated with a rapid disease course, with patients exhibiting a low propensity towards aggregate formation. In our study, the patients with the D101N mutation presented a similar clinical phenotype, with a relatively early age of onset and rapid ALS disease progression 30 . The fourth mutation we identified, p.D101G, is located in same site as p.D101N and was first detected in an ALS family from the UK 31 . In our study, all patients with the D101G mutation experienced a short disease duration. Both the D101N and D101G mutations have been shown to be associated with a rapidly progressing disease lasting approximately 2.5 years. This rapid disease progression may be caused by mutant SOD1 aggregation 30, 32, 33 . The final mutation we identified, p.C111Y, has been identified in North American, Japanese and Chinese families. The most common initial symptoms were primarily located in the spinal cord, and the disease progressed relatively slowly 34, 35 . According to our results, all five of these mutations were located in exon 4, which appears to be a hotspot of variation in comparison to other exons.
With regards to FUS mutations, to our knowledge, the p.P525_Y526insY mutation is the first reported in an ALS patient. This discovery broadens the spectrum of known genetic mutations in patients with ALS. The p.P525_Y526insY mutation is located in an Arg/Gly-rich region of the C-terminal domain of FUS that contains the nuclear localization signal (NLS) 36 . C-terminal fALS-associated FUS mutations affect the major NLS of the protein and thus impair its nuclear import 37 . The P525L mutation at the same site has shown the strongest degree of cytosolic mislocalization and was reported to cause especially aggressive forms of fALS 38, 39 . Thus, it is possible that the p.P525_Y526insY mutation disrupts nuclear import. The previously reported p.R521H mutation, located in a mutational hotspot region of the FUS gene, may result in aberrant localization and cytoplasmic accumulation of the mutant FUS protein 40, 41 . Patients with the p.R521H mutation were prone to notice spinal symptoms first. Moreover, the p.R521H mutation was shown to correlate with a longer disease course 42 . In fact, several FUS mutations cause disease characteristics distinctive of ALS patients. The p.P525L variant, frameshift mutations and gene deletions were identified to associate with juvenile disease onset and aggressive disease duration 2, 43 . The p.R521C mutation were particularly associated with phenotypes of neck and proximal muscle weakness 44, 45 . In summary, this study not only verified the high frequency of SOD1 mutations in Chinese fALS or sALS patient groups, but it also highlighted the importance of FUS mutations in Chinese fALS groups and revealed that TARDBP mutations are an uncommon cause of sALS or fALS in Chinese populations. In addition, we identified one novel mutation and broadened the spectrum of known FUS mutations contributing to ALS. Meanwhile, we provided a basis for the further study of genotype-phenotype correlations.
Methods
Subjects. A total of 173 unrelated patients with ALS were recruited from the Department of Neurology, Xiangya Hospital. All patients were of Han nationality, and were from the central southern China region, including the provinces of Hunan, Hubei, Jiangxi, Henan, and Guangxi. All patients, including 158 sALS patients (male: 69.4%; age at onset: 49.4 ± 12.1 years) and 15 fALS patients (male: 66.7%; age of onset: 47.5 ± 12.2 years), met the EI Escorial criteria for ALS diagnosis 46 . The 500 healthy individuals that were matched by gender, age and geographic region (male: 67.0%; age at onset: 48.5 ± 12.5 years). They were from the Xiangya Hospital Health Center. This study was approved by the Ethics Committee of Xiangya Hospital of the Central South University in China (equivalent to an Institutional Review Board) and carried out in accordance with the approved guidelines. Written informed consent was obtained from all participants.
Mutation screening. Genomic DNA was extracted from peripheral blood leukocytes using standard methods. The quality and quantity of DNA were assessed with a fluorometer. All DNA samples were diluted to 50 ng/uL. Using Sanger sequencing, all patient DNA was screened for mutations in all exons of SOD1 (NM_000454.4) and TARDBP (NM_007375.3) and in exons 5-6 and exons 14-15 of FUS (NM_004960.3). All primers were designed by Primer 5 software to amplify coding regions of SOD1, TARDBP and FUS using polymerase chain reaction (PCR) and to flank non-coding regions. Primers and PCR reaction conditions are listed in Supplementary Data 1. PCR products were sequenced using identical forward and reverse primers with BigDye terminator v3.1 sequencing chemistry on an ABI 3730xl DNA analyzer (Applied Biosystems). The DNA sequences were analyzed using Sequencher software, version 4.2. When a novel mutation was found, we first confirmed whether it was a novel mutation using the HGMD database (http://www.hgmd.cf.ac.uk/ac) and the dbSNP database (http://www.ncbi. nlm.nih.gov/snp). We then screened for the presence of the novel mutations in healthy controls. Finally, we used SIFT online software to predict the pathogenicity of the novel variants.
Statistical analysis. Statistical analysis of clinical data was performed using SPSS 18.0 (SPSS, Inc., Chicago, IL). To compare the differences among the two groups, the Mann-Whitney U test was used for continuous variables and Chi-square test was used for categorical variables. The threshold of statistical significance was set at p < 0.05.
